|
| |
| KLSE: GLOTEC (5220) | GLOBALTEC FORMATION BERHAD | MAIN : Industrial Products |
| Last Price | Today's Change | Day's Range | Trading Volume |
| 0.44 |  +0.04 (10.00%) | 0.40 - 0.445 | 9,435,500 |
Financials
Market Cap: 118 Million
| Latest Audited Result: 30-Jun-2020
| Latest Quarter: 30-Sep-2020 [#1]
| ||||||||||||||||||||||||||||||||||||||||||||||||||
Annual (Unaudited) ( EPS: 0.87, P/E: 50.43 )
| T4Q Result ( EPS: 4.12, P/E: 10.67 )
| Annualized Result ( EPS: 15.96, P/E: 2.75 )
|
Business Performance
Business Performance (By Quarter)
| Trailing 4 Quarters | Trailing 8 Quarters | |||
|---|---|---|---|---|
| Available Quarters | 4 Quarters | 8 Quarters | ||
| Continuous Quarters Of Revenue Growth | 1 / 4 | 25.00% | 1 / 8 | 12.50% |
| Total Positive Profit Years | 2 / 4 | 50.00% | 5 / 8 | 62.50% |
| Continuous Quarters Of Positive Profit | 1 / 4 | 25.00% | 1 / 8 | 12.50% |
| Continuous Quarters Of Profit Growth | 1 / 4 | 25.00% | 1 / 8 | 12.50% |
| Continuous Quarters Of Adjusted EPS Growth | 1 / 4 | 25.00% | 1 / 8 | 12.50% |
| Total Dividend Years | 0 / 4 | 0.00% | 0 / 8 | 0.00% |
| Continuous Quarters Of Dividend | 0 / 4 | 0.00% | 0 / 8 | 0.00% |
| Continuous Quarters Of Dividend Growth | 0 / 4 | 0.00% | 0 / 8 | 0.00% |
| Continuous Quarters Of Adjusted Dps Growth | 0 / 4 | 0.00% | 0 / 8 | 0.00% |
| Average ROE | 1.13% | -0.44% | ||
| Average Net Profit Margin | 9.20% | -6.58% | ||
Business Performance (By Year)
| Last 5 Financial Years | Last 10 Financial Years | |||
|---|---|---|---|---|
| Available Years | 5 Years | 10 Years | ||
| Continuous Years Of Revenue Growth | 0 / 5 | 0.00% | 0 / 10 | 0.00% |
| Total Positive Profit Years | 1 / 5 | 20.00% | 2 / 10 | 20.00% |
| Continuous Years Of Positive Profit | 1 / 5 | 20.00% | 1 / 10 | 10.00% |
| Continuous Years Of Profit Growth | 2 / 5 | 40.00% | 2 / 10 | 20.00% |
| Continuous Years Of Adjusted EPS Growth | 2 / 5 | 40.00% | 2 / 10 | 20.00% |
| Total Dividend Years | 0 / 5 | 0.00% | 0 / 10 | 0.00% |
| Continuous Years Of Dividend | 0 / 5 | 0.00% | 0 / 10 | 0.00% |
| Continuous Years Of Dividend Growth | 0 / 5 | 0.00% | 0 / 10 | 0.00% |
| Continuous Years Of Adjusted Dps Growth | 0 / 5 | 0.00% | 0 / 10 | 0.00% |
| Average ROE | -5.03% | -4.64% | ||
| Average Net Profit Margin | -12.05% | -8.65% | ||
Key Result
Key Result
| T4Q | Annualized | Annual (Unaudited) | Last 10 FY Average | Last 5 FY Average | |
|---|---|---|---|---|---|
| Revenue | 147,829 | 145,392 | 164,447 | 221,037 | 197,633 |
| NP to SH | 11,095 | 42,984 | 2,348 | -14,953 | -12,825 |
| Dividend | 0 | - | - | - | - |
| Adjusted EPS | 4.12 | 15.96 | 0.87 | -5.56 | -4.77 |
| Adjusted DPS | 0.00 | 0.00 | 0.00 | - | - |
NP to SH = Net Profit Attributable to Shareholder, EPS = Earning Per Share, DPS = Dividend Per Share
All figures in '000 unless specified.
EPS & DPS's figures in Cent.
Growth
Growth (By Quarter)
| LQ QoQ | LQ YoY | CQ YoY | LQ vs Average of T4Q | LQ vs Average of T8Q | |
|---|---|---|---|---|---|
| Revenue | 81.95% | -31.37% | -31.37% | -1.65% | -19.99% |
| NP to Owner | 893.06% | 437.57% | 437.57% | 287.42% | 1,296.66% |
| Dividend | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Adj. EPS | 898.00% | 439.19% | 439.19% | 287.38% | 1,295.51% |
| Adj. DPS | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
LQ = Latest Quarter, CQ = Cumulative Quarter, T4Q = Trailing 4 Quarters, T8Q = Trailing 8 Quarters, QoQ = Quarter on Quarter, YoY = Year on Year
Growth (By Year)
| T4Q vs LFY | T4Q vs AL5FY | T4Q vs AL10FY | AQR vs LFY | AQR vs AL5FY | AQR vs AL10FY | LFY YoY | LFY vs AL5FY | LFY vs AL10FY | |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | -10.11% | -25.20% | -33.12% | -11.59% | -26.43% | -34.22% | -24.32% | -16.79% | -25.60% |
| NP to Owner | 372.53% | 186.51% | 174.20% | 1,730.66% | 435.14% | 387.45% | 112.15% | 118.31% | 115.70% |
| Dividend | 0.00% | 0.00% | 0.00% | - % | - % | - % | 0.00% | 0.00% | 0.00% |
| Adj. EPS | 373.56% | 186.43% | 174.14% | 1,734.48% | 434.82% | 387.19% | 112.12% | 118.25% | 115.66% |
| Adj. DPS | 0.00% | 0.00% | 0.00% | - % | - % | - % | 0.00% | 0.00% | 0.00% |
T4Q = Trailing 4 Quarters, T8Q = Trailing 8 Quarters, AL5FY = Average of Last 5 Financial Years, AL10FY = Average of Last 10 Financial Years, LFY = Latest Financial Year AQR = Annualized Quarter Result, YoY = Year on Year
| Trade this stock for as low as 0.05% brokerage. Find out more. |
 limfly20 Cut loss , wasting time here, if buy hwgb or solution / bintai already make some profit, all price up recently 19/10/2020 1:29 PM awesome20 related to auto industry..should get benefited from Bauto, Drbhicom price movement 15/11/2020 4:23 PM cccthierry doing plam oil as well... https://www.globaltec.com.my/index.php/resources/ 30/11/2020 9:59 AM hsyanbird Good earning. Will limit up for both mother and company warrant. Bought 2000lots waiting for big profit. 01/12/2020 1:04 AM mansaham1972 Waran plg cantik kalau dapat harga 8.5 sen.Apapun hari ini saya tetap masuk harga 9 sen sebab mother masih bertahan lebih 40 sen. 01/12/2020 7:57 PM abc123_2020 (Kuala Lumpur, 9th) The President of the Chinese President Tan Sri Wu Tianquan said that the coronavirus vaccine developed by China is currently in the third phase of clinical trials under the UN World Health Organization. Once it has passed the market and obtained my country’s halal certification After that, it can be emergency in our country. He said that President Hua fully supports the government's emergency response to the introduction of Chinese vaccines. In this regard, we are also prepared to cooperate with the governments of Malaysia and China and relevant parties, in accordance with all necessary regulations and regulations, to assist relevant enterprises in docking to introduce vaccines to Malaysia. Wu Tianquan is also the president of the Chinese Assembly Hall in Sabah. He recently communicated with the leadership of the agency’s chief executive, Dr. Akma Yusuf, at the headquarters of the Malaysian Clinical Research Institute (CRM) to understand the organization’s operating procedures. In a statement issued today, it said. According to the agency, relevant preparations have been made to introduce Chinese vaccines. Wu Tianquan said that President Hua is also actively contacting relevant Chinese parties, hoping to assist and coordinate the introduction of approved vaccines to Malaysia, and cooperate with all departments and institutions, including Malaysian clinical research institutions, to help my country connect with enterprises. Anti-epidemic work, especially in civilian epidemic prevention. He described that the Malaysian Clinical Research Institute was established in 2012 on the recommendation of the Malaysian Clinical Research Center (CRC), mainly to assist the government in managing overseas clinical research and to promote important work such as clinical research in my country. It is also well regulated by the National Pharmaceutical Regulatory Agency (NPRA) and the Medical Research and Ethics Committee (MREC). At the same time, Wu Tianquan, who is also the major shareholder and executive chairman of Elite Holdings Limited (GLOTEC, 5220, main board industrial stock), a company listed on the Kuala Lumpur Stock Exchange, said that the group's subsidiaries are also discussing participation in the project of introducing Chinese vaccines, hoping to help Give corporate feedback on the national anti-epidemic work. He said that in particular, the country is currently facing the third wave of attacks, and many regions in the country are trapped in yellow and red zones. After the implementation of the state closure and cross-county ban, the government, enterprises and businesses, including the people, must work together. Cooperate, comprehensively prevent and fight the epidemic, so as to flatten the curve as soon as possible. "This includes arrangements for the introduction of vaccines. We hope that vaccines can be approved for market as soon as possible to resolve the crisis." He pointed out that the Chinese government, through the Ministry of Science, Technology and Innovation, is also responsible for consulting with relevant Chinese government departments and institutions, and deciding on cooperation and procurement plans for COVID-19 vaccines. According to Carey, Minister of Science and Arts, the third phase clinical trial data of COVID-19 vaccine is expected to be analyzed by the end of this year. The department, the Ministry of Health and the General Prosecutor's Office are discussing relevant legal affairs and procurement models. 07/12/2020 11:26 AM hsyanbird Flat a few days... buy now before CPO price break 3700. This counter will fly accordingly. Glotec-wa more profit to go. TAYOR. 10/12/2020 10:57 AM Lim Bernard Tunggu sampai sampai leher pun mahu putus masih pun tak jalan buang lah tong sampag lebeh baik 10/12/2020 4:14 PM IbnuShaari those who patiently waiting will see the light at the end of the dark tunnel although the journey quite long. 11/12/2020 3:06 PM up41 The exceptional profit for the reporting quarter was due to a Gain on disposal of gold royalty of 22m ( refer to cashflow statements) . The reporting revenue & gross profit were down . 13/12/2020 11:31 AM IbnuShaari alahai elok2 dah stabilizes 43-44c, now gone down unsupported. Seems to be intentionally blocked for further going-up. What games is this? I can't really understand!... volume remains low for the force selling cause. Who is actually liquidating? The good quarterly result makes no diff. Seems to go back where it started at 38c! 21/12/2020 6:25 PM IbnuShaari Counter ni memang tak friendly. Tidurnya lebih dari jaga! kalau Jaga pun mcm orang kena gam, mamai2, lps tu terus tidur balik without wake-up! 29/12/2020 11:00 AM IbnuShaari The counter which never given a chance to make a profit for retailers. If you buy you will get stuck indefinitely. 29/12/2020 11:19 AM damansaraeagle Technically, it is not looking good for GLOTEC as its 20-Day Moving Average is sloping downward and its price action is below the Moving Average line. The recent downward movement in price has brought us to the technically important level of 0.395. Failure to find support at this level may accentuate the bearish move. The RSI indicator is giving a reading in the oversold region. This may indicate the price decline may be over-extended. The price and volume action at the 0.395 support level is to be monitored carefully. 08/01/2021 12:03 PM ask1961 Nobody play glotec aa? I sold everything today after long time keeping. No movement! 20/01/2021 5:19 PM Hew Kiong Peng George baru begin uptrend..must hold aa.net cash around 18sen limited downside n huge upside potential 20/01/2021 8:25 PM  |
|